These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. New antiestrogen shows promise in ER-positive breast cancers. Oncology (Williston Park); 1994 Aug; 8(8):58. PubMed ID: 7947003 [No Abstract] [Full Text] [Related]
3. [Hormonal dependence and hormonal therapy of cancers of the endometrium and breast]. Barrat J Rev Fr Gynecol Obstet; 1985 Jul; 80(7):549-53. PubMed ID: 4035192 [TBL] [Abstract][Full Text] [Related]
4. Histone deacetylase inhibitor induced modulation of anti-estrogen therapy. Thomas S; Munster PN Cancer Lett; 2009 Aug; 280(2):184-91. PubMed ID: 19185986 [TBL] [Abstract][Full Text] [Related]
5. [Anti-hormonal therapy in breast cancer]. Ecker-Schlipf B Med Monatsschr Pharm; 1994 Aug; 17(8):247-50. PubMed ID: 7935152 [No Abstract] [Full Text] [Related]
6. Use of estrogen antagonists and aromatase inhibitors in breast cancer and hormonally sensitive tumors of the uterine body. Gadducci A; Cosio S; Genazzani AR Curr Opin Investig Drugs; 2004 Oct; 5(10):1031-44. PubMed ID: 15535424 [TBL] [Abstract][Full Text] [Related]
7. Clinical development of fulvestrant ("Faslodex"). Howell A; Abram P Cancer Treat Rev; 2005; 31 Suppl 2():S3-9. PubMed ID: 16198055 [TBL] [Abstract][Full Text] [Related]
8. Optimizing endocrine therapy for breast cancer. Winer EP J Clin Oncol; 2005 Mar; 23(8):1609-10. PubMed ID: 15755964 [No Abstract] [Full Text] [Related]
9. [Action of SERM and SAS (tibolone) on breast tissue]. Gompel A; Jacob D; de Chambine S; Mimoun M; Decroix Y; Rostene W; Poitout P Contracept Fertil Sex; 1999 May; 27(5):368-75. PubMed ID: 10401183 [TBL] [Abstract][Full Text] [Related]
10. The combination of VEGF inhibitors and anti-oestrogen therapies in breast cancer. Banerjee S Steroids; 2011 Jul; 76(8):807-11. PubMed ID: 21439993 [TBL] [Abstract][Full Text] [Related]
11. [Mechanism and side effect of endocrine therapy]. Tsuda M; Ishiguro H; Saji S Nihon Rinsho; 2015 Feb; 73 Suppl 2():291-7. PubMed ID: 25831770 [No Abstract] [Full Text] [Related]
12. [Hormone treatment of breast cancer]. Gröhn P Duodecim; 1991; 107(8):603-10. PubMed ID: 1364913 [No Abstract] [Full Text] [Related]
15. Fulvestrant ('Faslodex'): current and future role in breast cancer management. Howell A Crit Rev Oncol Hematol; 2006 Mar; 57(3):265-73. PubMed ID: 16473018 [TBL] [Abstract][Full Text] [Related]
16. [Estrogens and cancer]. Bayard F Rev Prat; 1979 Apr; 29(21):1745-52. PubMed ID: 472622 [No Abstract] [Full Text] [Related]
17. [Steroid receptors and breast cancer therapy (author's transl)]. Pavicić S; Vujasinović B; Borcić-Komarek J; Kozumplik V; Seremet M; Popović T; Gamulin S Lijec Vjesn; 1978 Oct; 100(10):589-95. PubMed ID: 745491 [No Abstract] [Full Text] [Related]
18. Inhibition of estrogen-stimulated growth of uterine leiomyomas by selective estrogen receptor modulators. Fuchs-Young R; Howe S; Hale L; Miles R; Walker C Mol Carcinog; 1996 Nov; 17(3):151-9. PubMed ID: 8944075 [TBL] [Abstract][Full Text] [Related]